Compare DexCom, Inc. (DXCM) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Koninklijke Philips NV — how do they compare? DexCom, Inc. trades at $90.76 (market cap $33.79B), while Koninklijke Philips NV trades at $27.09 (market cap $26.58B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Koninklijke Philips NV pays a 3.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PHG | |
|---|---|---|
Market Cap | $33.79B | $26.58B |
Sector | Health | Health |
52-Week High | $90.80 | $32.91 |
52-Week Low | $54.84 | $25.02 |
Enterprise Value | $33.24B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
PHG trades at $26.86, down 0.3% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, while analyst sentiment remains mixed with 41% buy ratings.
The outlook appears cautiously optimistic with solid earnings momentum and institutional accumulation, though risks include order intake volatility and competitive pressures. The stock offers value characteristics with reasonable P/E of 20.5 and strong cash flow generation, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
